Core Viewpoint - The major shareholders and some directors and senior management of Chengdu Saintno Biological Technology Co., Ltd. have announced a share reduction plan due to personal funding needs and other financial considerations [1][2]. Shareholding Information - Sichuan Development Securities Investment Fund Management Co., Ltd. holds 11,407,021 shares, accounting for 7.2478% of the total share capital, with 431,021 shares acquired through centralized bidding [1][4]. - Vice General Manager Lu Changliang holds 386,316 shares, representing 0.2455% of the total share capital, with part of the shares obtained from the 2023 restricted stock incentive plan [1][5]. - Director and Vice General Manager Wang Xiaoli holds 2,298,786 shares, accounting for 1.4606% of the total share capital, with shares obtained before the IPO and from the 2023 incentive plan [1][5]. Reduction Plan Details - Sichuan Development plans to reduce up to 4,721,578 shares, not exceeding 3% of the total share capital, through centralized bidding and block trading [2][7]. - Lu Changliang plans to reduce up to 96,579 shares (0.0614%) and Wang Xiaoli plans to reduce up to 574,696 shares (0.3652%) within the same timeframe [2][7]. - The reduction period for all parties is set from September 15, 2025, to December 14, 2025 [7]. Previous Reduction Activities - Sichuan Development has previously reduced 1,128,207 shares (1.01%) between August 15, 2024, and August 26, 2024, at prices ranging from 24.7903 to 26.8438 yuan per share [6]. Compliance and Commitments - The shareholders have committed to adhere to relevant regulations regarding share reductions and have no current restrictions preventing them from executing the planned reductions [8][9].

Group 1 - Jiangsu Electric Power's controlling shareholder plans to increase its stake in the company by 4 billion to 8 billion yuan [2] - Eight A-share listed companies disclosed share reductions, including Shun'an Environment, Jiayuan Technology, and others [1][2] Group 2 - Shun'an Environment's major shareholder, Zijin Investment, intends to reduce its stake by no more than 3% [2] - Jiayuan Technology's directors and executives plan to collectively reduce their holdings by no more than 3.41% [2] - Xiwuli De Gain 1 intends to reduce its stake in Shunwei Co., Ltd. by 3% [2] - The controlling shareholder of Xinqianglian plans to reduce its stake by no more than 3% [2] - Hongta Innovation, a shareholder of Decai Co., Ltd., plans to reduce its stake by no more than 1% [2] - Shareholders of Saint Nuo Biological plan to reduce their holdings by no more than 3.43% [2] - Ningbo Sihui, a shareholder of Ananda, intends to reduce its stake by no more than 2% [2] - The second-largest shareholder of Wanye Enterprise plans to reduce its stake by no more than 2.76% [2]

Group 1 - Changjiang Electric Power's controlling shareholder plans to increase its stake by 4 billion to 8 billion yuan within the next 12 months through secondary market transactions [1] - Goer Technology's subsidiary intends to acquire 100% equity of Shanghai Aolai, enhancing its core competitiveness in micro-nano optical devices [2] - Huakin Technology is planning to issue H-shares and list on the Hong Kong Stock Exchange to accelerate internationalization and enhance overseas financing capabilities [3] Group 2 - Shuyou Shen has received a Phase I clinical research summary report for STSP-0902 eye drops, indicating good safety and tolerability [4] - Yuanlin Co. announced that it has no business related to graphene despite a significant stock price increase, emphasizing the lack of relevant technology and talent [5] - Newnow's subsidiary has received approval for clinical trials of SYS6036 injection, a humanized monoclonal antibody for tumor immunotherapy [6] Group 3 - Kaige Precision's net profit increased by 144% year-on-year in the first half of the year, with revenue of 454 million yuan [7][8] - Chipone Technology's shareholders plan to transfer 5% of the company's shares through a pricing inquiry due to personal funding needs [9] - Tailin Micro is planning to acquire all or part of the equity of Shanghai Panqi Microelectronics, with stock suspension expected for up to 10 trading days [10] Group 4 - Sihua New Materials stated that the application of liquid cooling technology will not significantly impact its operating performance in the short term [11] - Xin'ao Co. plans to privatize Xin'ao Energy Holdings through its wholly-owned subsidiary and has completed the necessary regulatory filings [12] - Jingwang Electronics intends to invest 5 billion yuan in expanding its Zhuhai Jinwan base to enhance its competitive advantage in high-end products [13] Group 5 - Huilv Ecology's subsidiary signed contracts for the construction of a light module production base with a total investment of 700 million yuan [14] - Zhongjian Technology has authorized management to initiate preparations for issuing H-shares and listing on the Hong Kong Stock Exchange [15] - Huayang Lianzhong's stock will be subject to risk warnings and will be renamed ST Huayang starting August 26 [16] Group 6 - Shengyang Co. plans to establish a joint venture to enter the open-source Hongmeng ecosystem business with a registered capital of 50 million yuan [18] - Jiangsu Guotai intends to use up to 12 billion yuan of idle funds for entrusted wealth management in low-risk financial products [19] - Ping An Bank reported a 3.9% decline in net profit for the first half of the year, with a proposed cash dividend of 2.36 yuan per 10 shares [20] Group 7 - Shenkong Co. reported a 926% increase in net profit for the first half of the year, driven by demand in the semiconductor industry [21] - Zhangjiang Hi-Tech's net profit grew by 38.64% year-on-year, with revenue of 1.704 billion yuan [22] - Silan Micro achieved a net profit of 265 million yuan in the first half of the year, reversing a loss from the previous year [23] Group 8 - Ganfeng Lithium reported a net loss of 531 million yuan in the first half of the year, impacted by price adjustments in the lithium industry [24] - Zhaoyi Innovation's net profit increased by 11.31% year-on-year, with revenue of 4.15 billion yuan [25] - Dongxin Co. reported a net loss of 111 million yuan in the first half of the year, despite a revenue increase [26] Group 9 - Pizaihuang's net profit decreased by 16.22% year-on-year, with total revenue of 5.379 billion yuan [27] - Luoyang Molybdenum's net profit increased by 60% year-on-year, achieving a revenue of 94.773 billion yuan [28] - Tongwei Co. reported a net loss of 4.955 billion yuan in the first half of the year, primarily due to price adjustments in the photovoltaic industry [29] Group 10 - Chunzong Technology reported a net loss of 40 million yuan in the first half of the year, with a significant revenue decline [30] - China CNR's net profit increased by 72.48% year-on-year, with a proposed cash dividend of 1.1 yuan per 10 shares [31] - Shennuo Bio's shareholders plan to reduce their holdings by up to 3.43% [32]

Group 1 - The controlling shareholder of Changjiang Electric Power plans to increase its stake in the company by 4 to 8 billion yuan [1] - Shareholder Xibu Lide intends to reduce its stake in Sunway Shares by no more than 3% [1] - Shareholders Chuanfa Investment, Lu Changliang, and Wang Xiaoli plan to collectively reduce their stake in Saint Noble Bio by no more than 3.43% [1]

圣诺生物8月22日公告，股东川发投资拟减持不超过4,721,578股，占公司总股本的3%；副总经理卢昌亮 拟减持不超过96,579股，占公司总股本的0.0614%；董事、副总经理王晓莉拟减持不超过574,696股，占 公司总股本的0.3652%。减持期间为2025年9月15日至12月14日。 ...

证券代码：688117 证券简称：圣诺生物 公告编号：2025-025 成都圣诺生物科技股份有限公司 持股 5%以上股东及部分董事、高级管理人员 减持股份计划公告 公司于近日收到卢昌亮先生、王晓莉女士出具的《关于股东减持计划的告知 函》,因个人资金需求，卢昌亮先生、王晓莉女士拟通过集中竞价或大宗交易的 方式减持其持有的公司股份。卢昌亮先生拟减持数量不超过 96,579 股，即不超 过公司总股本的 0.0614%，王晓莉女士拟减持数量不超过 574,696 股，即不超过 公司总股本的 0.3652%，减持期间为本公告披露之日起 15 个交易日之后的 3 个 月内。 如遇派息、送股、转增股本、配股等除权除息事项，上述拟减持股份数量将 相应进行调整，但减持股份占公司总股本的比例不变。 现将具体情况公告如下： 注：拟减持股份来源于协议转让取得及集中竞价取得的股份（含前述股份在公司首次公开发 2 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东及部分董事、高级管理人员持有股份的基本情况 截至本公告披 ...

圣诺生物8月22日晚间发布公告称，公司于近日收到股东川发投资出具的《关于股东减持计划的告知 函》因股东自身资金需求，川发投资拟通过集中竞价、大宗交易的方式减持其持有的公司股份合计不超 过约472.16万股，即不超过公司总股本的3%。拟通过集中竞价方式减持的部分，自本公告披露之日起 15个交易日之后的3个月内进行且任意连续90个自然日内减持的股份总数不超过公司股份总数的1%；拟 通过大宗交易方式减持的部分，自本公告披露之日起15个交易日之后的3个月内进行且任意连续90个自 然日内减持的股份总数不超过公司股份总数的2%。公司于近日收到卢昌亮先生、王晓莉女士出具的 《关于股东减持计划的告知函》因个人资金需求，卢昌亮先生、王晓莉女士拟通过集中竞价或大宗交易 的方式减持其持有的公司股份。卢昌亮先生拟减持数量不超过约9.66万股，即不超过公司总股本的 0.0614%，王晓莉女士拟减持数量不超过约57.47万股，即不超过公司总股本的0.3652%，减持期间为本 公告披露之日起15个交易日之后的3个月内。 （文章来源：每日经济新闻） ...

格隆汇8月22日丨圣诺生物(688117.SH)公告称，股东川发投资拟减持不超过4,721,578股，占公司总股本 的3%；副总经理卢昌亮拟减持不超过96,579股，占公司总股本的0.0614%；董事、副总经理王晓莉拟减 持不超过574,696股，占公司总股本的0.3652%。减持期间为2025年9月15日至12月14日。 ...

公司于近日收到卢昌亮先生、王晓莉女士出具的《关于股东减持计划的告知函》,因个人资金需求，卢 昌亮先生、王晓莉女士拟通过集中竞价或大宗交易的方式减持其持有的公司股份。卢昌亮先生拟减持数 量不超过96,579股，即不超过公司总股本的0.0614%，王晓莉女士拟减持数量不超过574,696股，即不超 过公司总股本的0.3652%，减持期间为本公告披露之日起15个交易日之后的3个月内。 格隆汇8月22日丨圣诺生物(688117.SH)公布，公司于近日收到股东川发投资出具的《关于股东减持计划 的告知函》,因股东自身资金需求，川发投资拟通过集中竞价、大宗交易的方式减持其持有的公司股份 合计不超过4,721,578股，即不超过公司总股本的3%。拟通过集中竞价方式减持的部分，自本公告披露 之日起15个交易日之后的3个月内进行,且任意连续90个自然日内减持的股份总数不超过公司股份总数的 1%；拟通过大宗交易方式减持的部分，自本公告披露之日起15个交易日之后的3个月内进行,且任意连 续90个自然日内减持的股份总数不超过公司股份总数的2%。 ...

Core Viewpoint - The announcement from Shengnuo Biotech indicates that significant shareholders plan to reduce their holdings, which may impact the company's stock performance and investor sentiment [1] Shareholder Reduction Plans - Shareholder Chuanfa Investment intends to reduce its holdings by up to 4,721,578 shares, representing 3% of the company's total share capital [1] - Vice General Manager Lu Changliang plans to reduce his holdings by up to 96,579 shares, accounting for 0.0614% of the total share capital [1] - Director and Vice General Manager Wang Xiaoli plans to reduce her holdings by up to 574,696 shares, which is 0.3652% of the total share capital [1] - The reduction period is set from September 15, 2025, to December 14, 2025 [1]